Lamotrigine found to prevent NF1 brain tumour growth in mice
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
List view / Grid view
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have uncovered the role of the PL-BLA neuronal axis and its potential function in DOP-mediated anxiolytic effects.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
The new study suggests that this gene therapy method may combat ARVC in both early and more advanced stages of the condition.
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
In vitro and in vivo experiments highlight the advantages of a new targeted spectroscopy system for many eye diseases.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Advancements in enzyme-activated near-infrared fluorescent probes hold promise for evaluating responses to enzyme-targeting therapies.